Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.

@article{Nakajima2005PharmacokineticsOP,
  title={Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.},
  author={Miki Nakajima and Yuto Fujiki and Satoru Kyo and Taro Kanaya and Mitsuhiro Nakamura and Yoshiko Maida and Masaaki Tanaka and Masaki Inoue and Tsuyoshi Yokoi},
  journal={Journal of clinical pharmacology},
  year={2005},
  volume={45 6},
  pages={
          674-82
        }
}
Interindividual differences in the pharmacokinetics of paclitaxel and its metabolites in Japanese ovarian cancer patients were investigated in relation to genetic polymorphisms of the CYP2C8, CYP3A4, and MDR1 genes. The area under the concentration-time curve (AUC) ratios of paclitaxel/6alpha-hydroxypaclitaxel and paclitaxel/3 -p-hydroxypaclitaxel calculated as the metabolic index of CYP2C8 and CYP3A4 showed 13- and 12-fold interindividual variations, respectively. No patient had any CYP2C8… CONTINUE READING
Highly Cited
This paper has 36 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 1 Excerpt